Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Proxygen GmbH
See Emerging Company Profile .
BioCentury | Sep 19, 2023
Emerging Company Profile
Magnet: taking molecular glues beyond protein degradation with $50M
The company discovers small molecules that induce desired protein-protein interactions using an arsenal of screening technologies
BioCentury | Aug 1, 2023
Deals
Pharma deals seek novelty with heavy focus on first in class
An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
BioCentury | Apr 6, 2023
Deals
April 5 Quick Takes: Farallon seeking change at Exelixis
Plus: molecular glue deals for Proxygen, BioTheryX and updates from Ginkgo and Protagonist
BioCentury | Nov 11, 2022
Product Development
Molecular glue degraders: moving beyond IMiDs
Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases
BioCentury | Jun 4, 2022
Regulation
June 3 Quick Takes: myocarditis risk weighs on Novavax stock
Plus venture money for Vizgen, Watchmaker, Latch Bio, Endpoint Health
BioCentury | Feb 2, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging companies
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury | Mar 6, 2021
Emerging Company Profile
Proxygen’s knockout take on targeted protein degradation
Emerging Company Profile: Vienna’s Proxygen is taking a ligase-agnostic approach to finding molecular glues with therapeutic effects
Items per page:
1 - 7 of 7